Clinical Trial Update: CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CD7 CAR T cells (RD13-02) for relapsed/refractory severe aplastic anemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• CD7 CAR T Cells (RD13-02) (CD7 CAR T cells)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Severe Aplastic Anemia, Relapse | Phase 1 | Status: RECRUITING